Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.